Apyx Medical (NASDAQ:APYX) Stock Rating Upgraded by Craig Hallum

Apyx Medical (NASDAQ:APYX) was upgraded by equities researchers at Craig Hallum to a “strong-buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

APYX has been the subject of several other research reports. BTIG Research initiated coverage on Apyx Medical in a research note on Thursday, October 17th. They issued a “neutral” rating for the company. JMP Securities reiterated a “market perform” rating on shares of Apyx Medical in a report on Monday, September 16th.

Apyx Medical Price Performance

Shares of APYX opened at $1.21 on Thursday. Apyx Medical has a 12-month low of $0.97 and a 12-month high of $3.26. The business has a 50-day simple moving average of $1.22 and a two-hundred day simple moving average of $1.34. The company has a quick ratio of 4.45, a current ratio of 5.33 and a debt-to-equity ratio of 2.26. The stock has a market cap of $41.92 million, a PE ratio of -1.83 and a beta of 1.20.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, August 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The firm had revenue of $12.15 million during the quarter, compared to analyst estimates of $12.67 million. Apyx Medical had a negative return on equity of 105.45% and a negative net margin of 57.86%. During the same period in the previous year, the company earned ($0.11) EPS. Analysts anticipate that Apyx Medical will post -0.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apyx Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC acquired a new position in shares of Apyx Medical during the first quarter valued at about $676,000. Kingsview Wealth Management LLC raised its holdings in shares of Apyx Medical by 156.7% during the first quarter. Kingsview Wealth Management LLC now owns 31,028 shares of the company’s stock valued at $42,000 after purchasing an additional 18,943 shares during the period. Perkins Capital Management Inc. raised its holdings in shares of Apyx Medical by 7.0% during the first quarter. Perkins Capital Management Inc. now owns 228,500 shares of the company’s stock valued at $311,000 after purchasing an additional 15,000 shares during the period. Rathbones Group PLC raised its holdings in shares of Apyx Medical by 148.0% during the second quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock valued at $337,000 after purchasing an additional 150,000 shares during the period. Finally, RPg Family Wealth Advisory LLC acquired a new position in shares of Apyx Medical during the second quarter valued at about $101,000. 55.33% of the stock is owned by institutional investors.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.